We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Noven Pharmaceuticals announced that the United States District Court for the
Southern District of Florida has issued an order dismissing without prejudice
a lawsuit filed against Noven and certain individual defendants styled In re
Noven Pharmaceuticals Securities Litigation.
Argonaut Technologies announced it has amended its definitive agreement with
Biotage AB of Uppsala, Sweden to increase the purchase price to $21.2 million
in cash and to include the sale of certain assets (excluding receivables) and
the assumption of specified liabilities, including warranty service and maintenance,
and accounts payable of up to $350,000 associated with its remaining Process
Development Products and Services.
Dutch biotechnology company Crucell
N.V. announced that it has extended its Cooperative Research and Development
Agreement (CRADA) with the Vaccine Research Center (VRC), part of the National
Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes
of Health (NIH), for the development of vaccines to protect against Ebola, Marburg
and Lassa infections.
In a victory for pharmaceutical firms, a federal appeals court has overruled
an FTC mandate that attempted to prevent drug patent holders from paying generic
manufacturers to keep less-expensive versions of branded products off the market.
An FDA advisory committee voted unanimously to recommend approval of Bristol-Myers
Squibb's (BMS) Baraclude, an investigational oral antiviral agent under development
for the treatment of chronic hepatitis B.
The FDA has pushed back its timetable for a major
restructuring of the Office of New Drugs (OND), but some activities already
are moving forward at the OND, including in the office that reviews cancer products.
Inex Pharmaceuticals Corp. has agreed to end a collaboration with Enzon Pharmaceuticals
Inc. for developing the Marqibo cancer drug after U.S. regulators rejected accelerated
approval for the medicine.